COVID-19神经精神后遗症的诊断与管理知识缺口
本文综述了COVID-19急性后遗症(PASC)神经精神症状的流行病学与病理生理机制,指出至少一种PASC神经精神症状在COVID-19住院患者6个月时报告率高达90%,在非住院成人中约25%。机制尚未明确,可能包括急性期脑损伤、神经退行性变、自身免疫与慢性炎症、病毒持续存在或潜伏病毒再激活,当前文献异质性大且存在定义、表型、生物标志物等知识缺口。
要点
- 至少一种PASC神经精神症状在COVID-19住院患者6个月时报告率高达90%,非住院成人约25%。
- 神经精神PASC机制尚未明确,可能涉及急性期脑损伤、神经退行性变、自身免疫炎症、病毒持续或潜伏病毒再激活。
- 当前文献异质性大,知识缺口包括PASC定义不一、缺乏标准化表型或生物标志物、病毒基因型差异、 ascertainment偏倚及社会决定因素考量有限。
核心结论
- growing data支持PASC神经精神症状高 prevalence,但当前文献异质性大且关键流行病学因素评估不一。
- RECOVER多中心研究计划通过大样本和先进评估帮助阐明PASC流行病学、病理生理和损伤机制,并确定治疗干预靶点。
研究设计与样本
- 本文为综述,基于PubMed来源(JAMA Psychiatry)文献,总结PASC神经精神后遗症的诊断与管理知识缺口。
主要发现
- 至少一种PASC神经精神症状在COVID-19住院患者6个月时报告率高达90%。
- 至少一种PASC神经精神症状在非住院COVID-19成人中报告率约25%。
- 神经精神PASC机制仍在阐明中,可能包括急性COVID-19期间累积的静态脑损伤、急性COVID-19继发效应触发的神经退行性变、伴慢性炎症的自身免疫机制、组织储库中的病毒持续存在或其他潜伏病毒的再激活。
- 知识缺口包括PASC定义可变、缺乏标准化表型或生物标志物、病毒基因型变异、 ascertainment偏倚以及对社会健康决定因素和大流行相关应激源的考量有限。
关键数值与推荐
- 至少一种PASC神经精神症状在COVID-19住院患者6个月时报告率高达90%。
- 至少一种PASC神经精神症状在非住院COVID-19成人中报告率约25%。
- 常见PASC神经精神症状包括认知障碍、睡眠困难、抑郁、创伤后应激和物质使用障碍。
临床怎么用
- 临床应关注COVID-19急性后遗症患者中认知障碍、睡眠困难、抑郁、创伤后应激和物质使用障碍等神经精神症状的评估。
- RECOVER研究计划通过大样本和先进评估阐明PASC流行病学、病理生理和损伤机制,并确定治疗干预靶点。
局限性
- 当前文献异质性大,关键流行病学因素评估不一。
- PASC定义可变、缺乏标准化表型或生物标志物、病毒基因型变异、 ascertainment偏倚以及对社会健康决定因素和大流行相关应激源的考量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neuropsychiatric symptoms have been reported as a prominent feature of postacute sequelae of COVID-19 (PASC), with common symptoms that include cognitive impairment, sleep difficulties, depression, posttraumatic stress, and substance use disorders. A primary challenge of parsing PASC epidemiology and pathophysiology is the lack of a standard definition of the syndrome, and little is known regarding mechanisms of neuropsychiatric PASC. OBSERVATIONS: Rates of symptom prevalence vary, but at least 1 PASC neuropsychiatric symptom has been reported in as many as 90% of patients 6 months after COVID-19 hospitalization and in approximately 25% of nonhospitalized adults with COVID-19. Mechanisms of neuropsychiatric sequelae of COVID-19 are still being elucidated. They may include static brain injury accrued during acute COVID-19, neurodegeneration triggered by secondary effects of acute COVID-19, autoimmune mechanisms with chronic inflammation, viral persistence in tissue reservoirs, or reactivation of other latent viruses. Despite rapidly emerging data, many gaps in knowledge persist related to the variable definitions of PASC, lack of standardized phenotyping or biomarkers, variability in virus genotypes, ascertainment biases, and limited accounting for social determinants of health and pandemic-related stressors. CONCLUSIONS AND RELEVANCE: Growing data support a high prevalence of PASC neuropsychiatric symptoms, but the current literature is heterogeneous with variable assessments of critical epidemiological factors. By enrolling large patient samples and conducting state-of-the-art assessments, the Researching COVID to Enhance Recovery (RECOVER), a multicenter research initiative funded by the National Institutes of Health, will help clarify PASC epidemiology, pathophysiology, and mechanisms of injury, as well as identify targets for therapeutic intervention.
引用
- Frontera JA, Simon NM. Bridging Knowledge Gaps in the Diagnosis and Management of Neuropsychiatric Sequelae of COVID-19. JAMA Psychiatry. 2022. PMID: 35767287. doi:10.1001/jamapsychiatry.2022.1616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。